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Introduction
The	preponderance	of	Clostridium	Difficile	(C-Diff)	cases	within	
the	hospital	setting	has	been	well	noted.	C-Diff	infection	(CDI)	is	
an	antibiotic	resistant	bacterium	that	is	widely	recognized	and	
currently	noted	to	be	the	“most	common	and	costly	healthcare	
associated	infection	in	the	United	States”	(Abt,	McKenney	&	
Pamer,	2016).	The	topic	of	CDI	is	important	to	discuss,	as	this	
infection	can	attack	all	patient	populations	especially	those	
following	antibiotic	treatment.	A	disruption	in	a	person’s	
intestinal	microbiota	is	known	to	place	the	them	at	higher	risk	for	
CDI (Abt,	McKenney	&	Pamer,	2016).	The	growing	prevalence,	
antibiotic	resistance	associated	with	this	bacterium,	increased	
associated	healthcare	costs,	high	rates	of	re-occurrence,	high	
rates	of	healthcare	associated	cases	and	high	rates	of	mortality	
make	it	a	significant	current	problem	facing	the	profession	of	
medicine	today.	
CDI	is	a	complex	issue	that	requires	more	education	and	
knowledge	surrounding		the	disease	and	the	pathophysiological	
processes	involved.	The	purpose	of	this	presentation	is	to	
educate	and	inform	individuals	on	the	important	details	
surrounding	CDI.	The	pathophysiology	of	the	infection,	associated	
signs	&	symptoms,	along	with	implications	for	nursing	care	will	be	
discussed.
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• In	conclusion,	C-diff	is	a	complex	infection	with	a	growing	
incidence	and	burden	impacting	patients	around	the	world.	
• Being	aware	of	the	importance	of	early	recognition	and	treatment	
can	help	to	reduce	the	complications	associated	with	advanced	
CDI.	
• By	understanding	the	pathophysiology	surrounding	this	
bacterium,	healthcare	providers	can	work	to	ensure	they	are	
practicing	in	a	way	that	is	evidenced	based	and	accurate.	
• As	mentioned,	nurses	alone	have	many	responsibilities	that	can	
positively	impact	outcomes	associated	with	CDI.	It	is	the	
responsibility	however,	of	all	healthcare	providers	to	ensure	they	
are	following	strict	protocols	to	limit	the	effects	of	this	devastating	
illness.	
Underlying	Pathophysiology
“The	last	clinical	phase	is	the	window	of	vulnerability.	This	is	described	as	the	
window	for	recurrence	as	a	result	of	CDI	treatment.	Unfortunately,	the	antibiotics	
used	typically	to	treat	CDI	not	only	suppresses	C-diff,	but	also	attack	the	normal	
intestinal	microbiota.	Until	the	normal	flora	recovers,	there	is	an	opportunity	for	C-
diff spores	that	survived	treatment,	to	then	proliferate	and	re-infect	(Yacyshyn,	
2016).	“The	period	of	vulnerability	starts	at	the	time	of	the	sub	inhibitory	levels	of	
the	CDAD	antibiotics	and	ends	with	recovery	of	the	intestinal	microbiota”	(Yacyshyn,	
2016).
Signs	&	Symptoms
Symptoms	of	CDI	can	vary	depending	on	the	severity	of	the	
infection.	In	fact,	an	individual	could	simply	be	a	carrier	for	the	
infection	while	showing	no	signs	or	symptoms	of	actually	having	
it.	“Three	or	more	watery,	nonbloody	stools	per	24-h	period	is	the	
hallmark	of	symptomatic	illness”	(Ofosu,	2016).	Signs	and	
symptoms	of	CDI	are	provided	below		and	are	categorized	by	
severity	of	illness.	
• Mild	disease	is	characterized	by	diarrhea	in	the	absence	of	
signs	and	symptoms	of	colitis.
• Moderate	disease	is	characterized	by	moderate	diarrhea	with	
colitis	manifested	by	fever,	abdominal	cramps	and	
discomfort,	usually	in	the	lower	quadrants.	
• Severe	disease	is	characterized	by	white	blood	cell	count	of	
>15,000	cells/μL,	serum	albumin	<3	g/dL,	and/or	a	serum	
creatinine	level	≥1.5	times	the	premorbid	level”	(Ofosu,	
2016).	
Implications	for	Nursing	Care
• First,	nurses	must	ensure	that	they	adhere	to	and	promote	CDI	
protocols.	This	includes	washing	hands	with	soap	and	water	after	
patient	contact	and	strictly	following	contact	isolation	protocols.	
• Nurses	can	positively	impact	the	process	surrounding	CDI	by	educating	
patients	on	the	importance	of	taking	antibiotics	as	prescribed.	
Educating	on	the	negative	outcomes	that	can	result	from	not	following	
prescribed	directions	is	also	essential.	
• Nurses	are	at	the	frontlines	in	healthcare	and	have	the	most	patient	
contact.	As	a	result,	nurses	must	be	aware	of	the	common	signs	and	
symptoms	that	follow	CDI.	By	recognizing	CDI	early,	nurses	can	alert	
physicians	to	promote	early	recognition	and	treatment.	
• Place	patients	that	are	thought	to	potentially	have	C-diff in	
presumptive	isolation	will	help	to	reduce	the	spread	of	CDI.	
• Lastly,	nurses	can	advocate	for	patients	by	recognizing	those	at-risk;	
whether	on	antibiotics	or	immunocompromised	and	ensure	a	
probiotics	is	prescribed	to	sustain	the	normal	intestinal	microbiota,	
thus,	limiting	a	patients	risk	of	acquiring	CDI.
Diagram	1:	CDI	symptoms.	Retrieved	from	http://gi-
north.com/clostridium-difficile-aka-c-diff-aka-deadly-diarrhea/	
1)	Microbial	Suppression
2)	Collateral	Damage
3)	Window	of	Vulnerability
Significance	of	Pathophysiology
There	is	much	significance	behind	understanding	the	complexities	of	the	
pathophysiological	concepts	of	CDI.	As	discussed	above,	the	discovery	surrounding	
the	characteristics	of	C-diff spores	lead	to	the	recognition	that	C-diff is	resistant	to	
common	disinfectants	like	ethanol-based	hand	sanitizers.	This	subsequently	
resulted	in	new	protocols	requiring	providers	to	wash	their	hands	with	soap	and	
water	after	each	contact	with	a	patient	infected	by	C-diff.	Ultimately,	this	discovery	
was	helpful	in	reducing	the	communicability	associated	with	CDI.
Another	significant	concept	surrounding	the	pathophysiology	of	CDI	is	the	bacteria’s	
resistance	to	common	treatment.	This	is	ultimately	what	makes	this	infection	so	
difficult	to	manage.	Understanding	this	concept	has	brought	to	fruition	the	
importance	of	appropriate	antibiotic	prescribing,	administration	and	adherence.	
With	an	advanced	understanding	of	antibiotic	resistant	organisms	like	C-diff	from	a	
pathophysiology	standpoint,	further,	more	effective	advancements	in	technology	
and	treatment	will	arrive,	leading	to	exceedingly	desirable	outcomes.	
Conclusion
Diagram	2:	Pathophysiology	and	natural	history	of	Clostridium	difficile.	Retrieved	from	
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious-
disease/clostridium-difficile-infection/	
The	normal	intestinal	microbiota	is	generally	able	to	provide	resistance	against	CDI.	
However,	when	suppression	of	the	normal	protective	intestinal	microbiota	occurs,	
bacteria	like	C-diff can	begin	to	proliferate	in	the	colon.	This	is	most	typically	seen	as	a	
result	of	prolonged	antibiotic	treatment.	“Subsequent	ingestion	of	C	difficile,	which	is	
ubiquitous,	leads	to	germination	of	C	difficile	spores	and	growth	of	toxin-producing	
cells	that	change	the	gastrointestinal	epithelium	and	invoke	an	immune	response,	
leading	to	the	collateral	damage	phase”	(Yacyshyn,	2016).	
“C.	diff is	a	Gram- positive,	spore-forming,	obligate	anaerobic	bacterium.	The	formation	
of	spores	enables	C.	diff to	survive	in	oxic	conditions,	which	contributes	to	transmission	
in	healthcare	settings	and	maybe	also	in	the	community”	(Abt,	McKenney,	&	Pamer,	
2016).	C.	diff	spores	are	unique	in	that	they	are	resistant	to	heat,	oxygen	and	common	
disinfectants,	such	as	ethanol-based	hand	sanitizers	commonly	used	in	healthcare	
facilities	by	professionals	when	entering	and	leaving	patient	rooms	(Abt,	McKenney,	&	
Pamer,	2016).	This	characteristic	is	what	facilitates	the	spread	of	CDI.	Once	the	
environment	is	right,	subsequent	ingestion	of	C-diff leads	to	the	creation	of	spores	and	
cells	that	produce	a	toxin	able	to	changes	the	epithelial	lining	of	the	colon	(Yacyshyn,	
2016).	This	leads	to	an	activation	of	the	immune	response	resulting	in	the	symptoms	
described	above	and	is	what	finalizes	the	collateral	damage	clinical	phase.
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